Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.48M | -7.88M | -2.33M | -4.14M | -6.09M |
| Total Depreciation and Amortization | 404.70K | 425.60K | 428.80K | 446.50K | 443.20K |
| Total Amortization of Deferred Charges | 190.40K | 190.40K | 190.40K | -10.70K | 10.70K |
| Total Other Non-Cash Items | -2.19M | 6.44M | -2.02M | 1.68M | 2.48M |
| Change in Net Operating Assets | -388.00K | -1.52M | 1.28M | -2.77M | -1.67M |
| Cash from Operations | -3.47M | -2.34M | -2.46M | -4.79M | -4.83M |
| Capital Expenditure | -2.10K | -69.20K | -151.70K | -18.20K | -45.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -45.10K | -55.00K | -146.60K | -101.60K | -81.80K |
| Cash from Investing | -47.20K | -124.20K | -298.40K | -119.90K | -127.00K |
| Total Debt Issued | -- | 0.00 | 0.00 | 15.00M | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -4.38M | -625.00K |
| Issuance of Common Stock | 6.83M | 166.90K | -- | 0.00 | 53.20K |
| Repurchase of Common Stock | -- | -- | -41.50K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -57.60K | -790.40K | -- |
| Cash from Financing | 6.83M | 166.90K | -99.00K | 9.83M | -571.80K |
| Foreign Exchange rate Adjustments | 25.90K | -105.90K | 85.20K | -69.80K | 5.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.35M | -2.41M | -2.77M | 4.85M | -5.52M |